A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

PHASE2CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

September 28, 2023

Study Completion Date

December 20, 2024

Conditions
Chronic Spontaneous Urticaria
Interventions
BIOLOGICAL

barzolvolimab

Subcutaneous Administration

DRUG

Matching Placebo

Subcutaneous Administration

Trial Locations (56)

1085

Semmelweis Egyetem, ÁOK, Bőr-, Nemikórtani és Bőronkológiai Klinika, Budapest

1307

Universitätsklinikum Dresden, Dresden

1500

WorthWhile Clinical Trials, Benoni

1504

Medical Center Iskar EOOD Office of Clinical Allergology, Sofia

1784

"Medical Center SYNEXUS SOFIA, EOOD", Sofia

1827

Ubuntu Clinical Research, Lenasia

1935

FCRN Clinical Trial Centre Vaal Triangle, Vereeniging

2113

Newtown Clinical Research, Johannesburg

3010

Hospital General Universitario de Alicante, Alicante

4001

Synapta Clinical Research, Durban

4002

"Diagnostic Consultative Center Pulmed EOOD", Plovdiv

"University Multiprofile Hospital for Active Treatment Sveti Georgi EAD", Plovdiv

4032

Debreceni Egyetem, ÁOK és KK, Bőrgyógyászati Tanszék és Bőrgyógyászati Klinika, Debrecen

4092

Dr Pj Sebastian, Durban

5000

Allergo-Derm Bakos Kft. Bőrgyógyászati Magánrendelő, Szolnok

7200

Outpatient clinic for individual practice for specialized outpatient medical care in allergology-Doctor Thalat Sally Cholak EOOD, Razgrad

7700

The University of Cape Town - Lung Institute, Cape Town

8900

Óbudai Egészségügyi Centrum Kft., Zalaegerszeg

8907

Hospital Bellvitge, Barcelona

9324

Iatros International, Bloemfontein

10134

Vahlberg & Pild Clinic, Tallinn

10461

Montefiore Medical Center/Subspeciality-Allergy and Immunology, The Bronx

12203

Charite - Institute of Allergology IFA Campus Benjamin Franklin, Berlin

20815

Institute for Asthma and Allergy, Chevy Chase

21162

Chesapeake Clinical Research, White Marsh

24105

Universitätsklinikum Schleswig-Holstein - Zentrum für entzündliche Hauterkrankunge, Kiel

26133

Klinikum Oldenburg gGmbH - Klinik f. Dermatologie u. Allergologie, Oldenburg

28027

Universidad de Navarra, Madrid

30625

Hannover Medical University, Hanover

35043

Universitaetsklinikum Giessen u. Marburg GmbH, Marburg

35249

Clinical Research Center of Alabama dba Allervie Clinical Research, Birmingham

40225

Universitätsklinikum Düsseldorf - Dermatologie, Düsseldorf

42301

Allergy & Asthma Specialists, PSC, Owensboro

48149

Universitätsklinikum Münster Klinik u. Poliklinik f. Dermatologie, Münster

48197

Respiratory Medicine Research Institute of Michigan, PLC, Ypsilanti

68198

University of Nebraska Medical Center, Omaha

69120

Universitätsklinikum Heidelberg - Dermatologie, Heidelberg

72205

Little Rock Allergy & Asthma CRC, Little Rock

80112

IMMUNOe Research Centers, Centennial

80337

LMU Klinikum - Klinik und Poliklinik für Dermatologie und Allergologie DASZ-Dermato-Allergologisches Studien Zentrum, München

83706

Treasure Valley Medical Research, Boise

85251

Medical Research of Arizona, Scottsdale

93301

Kern Research, Inc, Bakersfield

94063

Allergy & Asthma Consultants, Redwood City

0119

Healthy Future, Tbilisi

0159

Center of Allergy and Immunology, Tbilisi

0186

Multiprofile Clinic Consilium Medulla, Tbilisi

30-363

Centrum Medyczne Plejady, Krakow

31-624

Malopolskie Centrum Alergologii, Krakow

90-153

Uniwersytecki Szpital Kliniczny nr 1 w Lodzi, Lodz

20-573

Luxderm Specjalistyczny Gabinet Dermatologiczny Prof. Doroty Krasowskie, Lublin

45-401

Uniwersytecki Szpital Kliniczny w Opolu, Pododdział Chorób Wewnętrznych i Alergologii, Opole

21-600

Medicome Sp. z o.o., Oświęcim

87-100

Medicover Integrated Clinical Services Sp. Z.o.o., Torun

02-953

Klinika Ambroziak sp. z o.o., Warsaw

08003

Hospital del Mar, Barcelona

Sponsors
All Listed Sponsors
lead

Celldex Therapeutics

INDUSTRY

NCT05368285 - A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | Biotech Hunter | Biotech Hunter